GoodRx Holdings, Inc. cash flow to debt ratio of 30.93% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

GoodRx Holdings, Inc.'s free cash flow has increased 44.77% from $113.55M last year to $164.38M, signaling increasing performance

GoodRx Holdings, Inc.'s debt to equity ratio is 0.83, which means that the company's assets are unhealthy financed, signaling financial risk.

GoodRx Holdings, Inc.'s debt has increased relative to shareholder equity from 0.75 last year to 0.83 today, signaling weakened financials

GoodRx Holdings, Inc. has a net debt to EBITDA ratio of 1.52x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

GoodRx Holdings, Inc.'s interest coverage ratio is 1.97, which means that the company struggles to meet interest obligations, signaling financial risk.

GoodRx Holdings, Inc.'s profit margin has increased (0.03%) in the last year from 2.07% to 2.07%, signaling increasing performance

GoodRx Holdings, Inc.'s short-term assets of $643.10M exceed its short-term liabilities of $246.00M

GoodRx Holdings, Inc.'s return on assets of 0.69% is lower than the 5.00% threshold, indicating inefficient asset utilization

GoodRx Holdings, Inc.'s return on equity of 2.61%, is lower than 15.00%, indicating bad performance

GoodRx Holdings, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

GoodRx Holdings, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

GoodRx Holdings, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

GoodRx Holdings, Inc. has a free cash flow yield of 12.96%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

GoodRx Holdings, Inc.'s yearly earnings has increased 85.72% since last year from $16.39M to $30.44M, signaling increasing performance

GoodRx Holdings, Inc.'s yearly revenue has increased 0.57% since last year from $792.32M to $796.85M, signaling increasing performance

ROIC 2.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

GoodRx Holdings, Inc.'s 3-year revenue CAGR of 1.30% is positive, indicating growing revenue over the past 3 years

GoodRx Holdings, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

GoodRx Holdings, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

GoodRx Holdings, Inc. is undervalued relative to its fair value price of 9.11 based on Discounted Cash Flow model

GoodRx Holdings, Inc. has an earnings yield of 1.31%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

GoodRx Holdings, Inc. is undervalued relative to its fair value price of 4.36 based on EBITDA multiple model

GoodRx Holdings, Inc. has an EV/EBITDA ratio of 8.41x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

GoodRx Holdings, Inc. has insufficient data to evaluate this check.

GoodRx Holdings, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

GoodRx Holdings, Inc. has a price-to-book ratio of 1.92x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

GoodRx Holdings, Inc. has a price-to-sales ratio of 1.58x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue